WHO recommends Oxford’s COVID-19 vaccine for adults above 18 years

By Sayujya S, Desk Reporter
  • Follow author on
Representational Image

A World Health Organization (WHO) panel recommended the COVID-19 vaccine from Oxford university, developed in collaboration with drugmaker AstraZeneca, for all adults over 18, paving the way to speed up vaccinations in developing countries.

The recommendation may encourage more countries to use the vaccine broadly, after some European Union (EU) countries advised against giving it to the elderly, citing insufficient trial data involving older people.

The shot’s effect in older people is expected to be the same as for younger recipients, said Alejandro Cravioto, chairman of the WHO panel, in a briefing.

The move is good news for developing countries, many of which are waiting to administer their first shots as wealthier countries have already inoculated millions of residents.

AstraZeneca, which developed the vaccine with the University of Oxford, has pledged significant supplies to COVAX, a facility led by led by the Global Alliance for Vaccines and Immunization (GAVI), WHO, the Coalition for Epidemic Preparedness Innovations (CEPI) and others that aims to distribute vaccines equitably around the world

The WHO’s recommendation on the Oxford-AstraZeneca shot follows the organization’s decision to clear a vaccine from American firm Pfizer and its German partner BioNTech in December. The AstraZeneca shot is easier to deploy than other vaccines like Pfizer’s that need to be stored at ultra-cold temperatures, and costs less.

Virus variants

As mutated virus strains spread across the globe, concern has grown that they’ll impact vaccine efficacy. South Africa, where one of the variants was first identified last year, said it would pause a rollout of AstraZeneca’s vaccine after a trial showed it had limited efficacy against mild infections with the new strain.

AstraZeneca Chief Executive Officer Pascal Soriot said the shot should still protect against severe disease, and WHO officials underlined the benefits of continuing to use the vaccine even in variant-hit areas.

“We made the recommendation that even if there is a reduction in possibility of this vaccine having a full impact in its protection capacity, there’s no reason not to recommend its use, even in countries that have the circulation of variants,” Mr. Cravioto said.


COVAX said last month that it’s on track to deliver at least 2 billion doses, about two-thirds of which will go to lower-income economies, and to vaccinate at least a fifth of each participating country’s population by year’s end.

The WHO’s emergency use authorization is needed for COVAX to send the vaccines to participating countries, in order to ensure a product’s safety and efficacy for countries that might not have the resources to make the assessments themselves. Individual countries can still make their own decisions on the use of vaccines.

Stay updated: Pfizer-BioNTech to supply vaccine to COVAX scheme: Sources